LLY

984.89

+1.43%↑

JNJ

238.53

+0.56%↑

ABBV

229.74

+0.2%↑

NVS

159.88

-0.06%↓

AZN

194.07

-0.69%↓

LLY

984.89

+1.43%↑

JNJ

238.53

+0.56%↑

ABBV

229.74

+0.2%↑

NVS

159.88

-0.06%↓

AZN

194.07

-0.69%↓

LLY

984.89

+1.43%↑

JNJ

238.53

+0.56%↑

ABBV

229.74

+0.2%↑

NVS

159.88

-0.06%↓

AZN

194.07

-0.69%↓

LLY

984.89

+1.43%↑

JNJ

238.53

+0.56%↑

ABBV

229.74

+0.2%↑

NVS

159.88

-0.06%↓

AZN

194.07

-0.69%↓

LLY

984.89

+1.43%↑

JNJ

238.53

+0.56%↑

ABBV

229.74

+0.2%↑

NVS

159.88

-0.06%↓

AZN

194.07

-0.69%↓

Inicio・Lista de Acciones・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Abierto

SectorSalud

92.66 1.65

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

88.73

Máximo

93.01

Métricas clave
By Trading Economics
Ingresos	5.4M -48M
Ventas	6M 57M
BPA	-0.82
Margen de beneficio	-82.974
Empleados	283
EBITDA	5.1M -43M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+53.39% upside

Dividendos
By Dow Jones
Próximas Ganancias	6 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-94M 6.3B
Apertura anterior	91.01
Cierre anterior	92.66

Noticias sobre sentimiento de mercado

By Acuity

50%

168 / 351 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

60 / 65.58 Soporte y Resistencia

Rhythm Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

5 mar 2026, 23:01 UTC

Ganancias

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises - Update

5 mar 2026, 21:54 UTC

Ganancias

Costco Posts Higher 2Q Profit on Rising Sales, Membership Fees

5 mar 2026, 21:35 UTC

Principales Movimientos del Mercado

ServiceNow Shares Rise After CEO Says AI Can Add Value to Software

6 mar 2026, 00:00 UTC

Noticias de Eventos Importantes

Its Missile Threat Degraded, Iran Is Taking Fewer Shots at More Targets -- WSJ

5 mar 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Decline Amid Concerns About Energy Costs -- Market Talk

5 mar 2026, 23:33 UTC

Charlas de Mercado

Gold Edges Higher on Possible Technical Recovery -- Market Talk

5 mar 2026, 23:27 UTC

Charlas de Mercado

Middle East Fighting Will Prompt RBA to Delay Hike -- Market Talk

5 mar 2026, 22:54 UTC

Charlas de Mercado

Ganancias

Costco Sold a $150,000 Diamond Ring in 2Q -- Market Talk

5 mar 2026, 22:50 UTC

Charlas de Mercado

Woodside Has More Exposure to Rising Gas Prices Than Santos -- Market Talk

5 mar 2026, 22:48 UTC

Ganancias

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

5 mar 2026, 22:46 UTC

Ganancias

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises -- Update

5 mar 2026, 22:44 UTC

Ganancias

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

5 mar 2026, 21:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

5 mar 2026, 21:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

5 mar 2026, 21:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

5 mar 2026, 21:35 UTC

Ganancias

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

5 mar 2026, 21:32 UTC

Ganancias

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

5 mar 2026, 21:26 UTC

Ganancias

These Stocks Are Today's Movers: Broadcom, Trade Desk, Berkshire Hathaway, Rigetti, Corning, Ciena, Expedia, and More -- Barrons.com

5 mar 2026, 21:24 UTC

Ganancias

Costco February Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 20.8% >COST

5 mar 2026, 21:23 UTC

Ganancias

Costco February Same-Store Sales Ex-Changes in Gas and Foreign Exchange Rose 7% >COST

5 mar 2026, 21:22 UTC

Ganancias

Costco 2Q Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

5 mar 2026, 21:21 UTC

Ganancias

Costco February Digitally-Enabled Sales Rose 21.8% >COST

5 mar 2026, 21:21 UTC

Ganancias

Costco Total Co Comparable Sales for February Rose 7.9% >COST

5 mar 2026, 21:20 UTC

Ganancias

Costco February Net Sales Were $21.69 B >COST

5 mar 2026, 21:20 UTC

Ganancias

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

5 mar 2026, 21:20 UTC

Ganancias

Costco Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

5 mar 2026, 21:19 UTC

Ganancias

Costco 2Q Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 21.7% >COST

5 mar 2026, 21:18 UTC

Ganancias

Costco 2Q Digitally-Enabled Sales Rose 22.6% >COST

5 mar 2026, 21:18 UTC

Ganancias

Costco 2Q Same-Store Sales Up 7.4% >COST

5 mar 2026, 21:15 UTC

Ganancias

Costco 2Q EPS $4.58 >COST

Comparación entre iguales

Cambio de precio

Rhythm Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

53.39% repunte

Estimación a 12 meses

Media 140.29 USD 53.39%

Máximo 176 USD

Mínimo 110 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Rhythm Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

Comprar

Mantener

Vender

De acuerdo con 14 analistas que ofrecen calificaciones bursátiles a para Rhythm Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

60 / 65.58Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Sentimiento

By Acuity

168 / 351 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.